LoginRegister

    Torrent Pharma posts Q4 net loss of Rs 152 crore

    GarimaWritten by Garima   |  

    The company had posted a net profit of Rs 228 crore for the corresponding period of the previous fiscal, Torrent Pharma said in a filing to the BSE.


    New Delhi: Drug firm Torrent Pharmaceuticals May 20 reported a consolidated net loss of Rs 152 crore for the quarter ended March 31, 2019, mainly on account of exceptional items. The company had posted a net profit of Rs 228 crore for the corresponding period of the previous fiscal, Torrent Pharmaceuticals said in a filing to the BSE.


    The company's consolidated revenue from operations stood at Rs 1,856 crore for the quarter under consideration. It was Rs 1,708 crore for the same period a year ago.


    Read Also: Torrent Pharma recalls over 8.82 lakh bottles of Losartan Potassium tablets from US, Puerto Rico


    Net loss of Rs 152 crore for the fourth quarter is on account of exceptional items of Rs 357 crore and lower hedging gains, the company said.




    Out of Rs 357 crore exceptional items, Rs 217 crore pertains to impairment provision of certain intangible assets under development and goodwill recognised with respect to the acquisition of Bio-Pharm Inc and Rs 140 crore is in relation to product recalls made during the current year, it added.






    For the fiscal year ended March 2019, the company posted a net profit of Rs 436 crore as against Rs 678 crore for the previous fiscal year.




    The company's consolidated revenue from operations for the fiscal year ended March 2019 stood at Rs 7,673 crore as against Rs 5,950 crore for 2017-18.


    Read Also: Torrent Pharma gets certain USFDA observations for Indrad plant


    The company's board has declared a final dividend of Rs 4 per equity share, Torrent Pharmaceuticals said.

    AcquisitionBio PharmBSEconsiderationDrug firm Torrent Pharmaceuticalsequity shareFinancial resultsfiscal yearMarch-quarterpharmapharma newsShares Of Torrent PharmaceuticalsTorrent PharmaTorrent Pharma revenue
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Garima
    Garima

      Garima joined Medical Dialogues in the year 2017 and is currently working as a Senior Editor. She looks after all the Healthcare news pertaining to Medico-legal cases, MCI/DCI decisions, Medical Education issues, government policies as well as all the news and updates concerning Medical and Dental Colleges in India. She is a graduate from Delhi University. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

      © 2020 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X